{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:53:13Z","timestamp":1777866793386,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T00:00:00Z","timestamp":1253059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s10637-009-9320-y","type":"journal-article","created":{"date-parts":[[2009,9,15]],"date-time":"2009-09-15T02:10:59Z","timestamp":1252980659000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin\u2019s lymphoma: a consortium for improving survival of lymphoma (CISL) trial"],"prefix":"10.1007","volume":"29","author":[{"given":"Byeong-Bae","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Yiul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suk Joong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,16]]},"reference":[{"key":"9320_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"key":"9320_CR2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH (1995) BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588\u2013595","journal-title":"J Clin Oncol"},{"key":"9320_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0609.2006.00796.x","volume":"78","author":"P Schutt","year":"2007","unstructured":"Schutt P, Passon J, Ebeling P, Welt A, Muller S, Metz K, Moritz T, Seeber S, Nowrousian MR (2007) Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol 78:93\u2013101","journal-title":"Eur J Haematol"},{"key":"9320_CR4","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1200\/JCO.1993.11.6.1085","volume":"11","author":"C Wheeler","year":"1993","unstructured":"Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP et al (1993) Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 11:1085\u20131091","journal-title":"J Clin Oncol"},{"key":"9320_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000077995","volume":"66","author":"A Aviles","year":"2004","unstructured":"Aviles A, Neri N, Huerta-Guzman J, Fernandez R (2004) Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 66:197\u2013200","journal-title":"Oncology"},{"key":"9320_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101:1835\u20131842","journal-title":"Cancer"},{"key":"9320_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","volume":"92","author":"Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D","year":"2005","unstructured":"Ng M, Waters J, Cunningham D, Chau I, Horwich A, Hill M, Norman AR, Wotherspoon A, Catovsky D (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352\u20131357","journal-title":"Br J Cancer"},{"key":"9320_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s002779900150","volume":"79","author":"M Hanel","year":"2000","unstructured":"Hanel M, Kroger N, Hoffknecht MM, Peters SO, Metzner B, Fiedler F, Braumann D, Schubert JC, Illiger HJ, Hanel A, Kruger WH, Zeller W, Weh HJ, Hossfeld DK, Zander AR (2000) ASHAP\u2013an effective salvage therapy for recurrent and refractory malignant lymphomas. Ann Hematol 79:304\u2013311","journal-title":"Ann Hematol"},{"key":"9320_CR9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117\u2013122","journal-title":"Blood"},{"key":"9320_CR10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"WS Velasquez","year":"1994","unstructured":"Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E, Cabanillas F (1994) ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169\u20131176","journal-title":"J Clin Oncol"},{"key":"9320_CR11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/10428199909058470","volume":"34","author":"FB Hagemeister","year":"1999","unstructured":"Hagemeister FB (1999) The role of ifosfamide in the treatment of lymphomas. Leuk lymphoma 34:433\u2013441","journal-title":"Leuk lymphoma"},{"key":"9320_CR12","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","volume":"17","author":"CH Moskowitz","year":"1999","unstructured":"Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17:3776\u20133785","journal-title":"J Clin Oncol"},{"key":"9320_CR13","doi-asserted-by":"publisher","first-page":"iv18","DOI":"10.1093\/annonc\/mdj994","volume":"Suppl 4","author":"G Corazzelli","year":"2006","unstructured":"Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A (2006) Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive\/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol Suppl 4:iv18\u201324","journal-title":"Ann Oncol"},{"key":"9320_CR14","first-page":"14","volume":"9","author":"A Goldin","year":"1982","unstructured":"Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9:14\u201323","journal-title":"Semin Oncol"},{"key":"9320_CR15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586","journal-title":"J Clin Oncol"},{"key":"9320_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"9320_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/1097-0142(20010701)92:1<194::AID-CNCR1309>3.0.CO;2-3","volume":"92","author":"RE Millikan","year":"2001","unstructured":"Millikan RE, Plunkett WK, Smith TL, Williams DL, Logothetis CJ (2001) Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin. Cancer 92:194\u2013199","journal-title":"Cancer"},{"key":"9320_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0609.2005.00482.x","volume":"75","author":"ES Papageorgiou","year":"2005","unstructured":"Papageorgiou ES, Tsirigotis P, Dimopoulos M, Pavlidis N, Fountzilas G, Papageorgiou S, Economopoulos T (2005) Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. Eur J Haematol 75:124\u2013129","journal-title":"Eur J Haematol"},{"key":"9320_CR19","first-page":"550","volume":"43","author":"I Aurer","year":"2002","unstructured":"Aurer I, Durakovic N, Radman I, Nemet D, Zupancic-Salek S, Kovacevic-Metelko J, Bogdanic V, Sertic D, Mrsic M, Mikulic M, Labar B (2002) Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study. Croat Med J 43:550\u2013554","journal-title":"Croat Med J"},{"key":"9320_CR20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.1995.13.7.1734","volume":"13","author":"MA Rodriguez","year":"1995","unstructured":"Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 13:1734\u20131741","journal-title":"J Clin Oncol"},{"key":"9320_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92:35\u201341","journal-title":"Haematologica"},{"key":"9320_CR22","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/S0959-8049(99)00147-1","volume":"35","author":"F Recchia","year":"1999","unstructured":"Recchia F, De Filippis S, Rosselli M, Pompili P, Guerriero G, Rea S (1999) Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study. Eur J Cancer 35:1457\u20131461","journal-title":"Eur J Cancer"},{"key":"9320_CR23","first-page":"149","volume":"12","author":"B Sirohi","year":"2007","unstructured":"Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J, Chong G, Wotherspoon A (2007) Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology (Amsterdam, Netherlands) 12:149\u2013153","journal-title":"Hematology (Amsterdam, Netherlands)"},{"key":"9320_CR24","doi-asserted-by":"crossref","unstructured":"Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A (2009) Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma. Cancer chemother pharmacol","DOI":"10.1007\/s00280-009-0941-9"},{"key":"9320_CR25","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558\u2013565","journal-title":"Blood"},{"key":"9320_CR26","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","volume":"18","author":"T El Gnaoui","year":"2007","unstructured":"El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Divine M, Tabah-Fisch I, Reyes F, Haioun C (2007) Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 18:1363\u20131368","journal-title":"Ann Oncol"},{"key":"9320_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/10428190500312295","volume":"47","author":"N Di Renzo","year":"2006","unstructured":"Di Renzo N, Brugiatelli M, Montanini A, Vigliotti ML, Cervetti G, Liberati AM, Luminari S, Spedini P, Giglio G, Federico M (2006) Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. Leuk lymphoma 47:473\u2013479","journal-title":"Leuk lymphoma"},{"key":"9320_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdl395","volume":"18","author":"F Morschhauser","year":"2007","unstructured":"Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, Solal-Celigny P, Sebban C, Coiffier B, Chouaki N, Bauters F, Dumontet C (2007) Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 18:370\u2013375","journal-title":"Ann Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-009-9320-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9320-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-009-9320-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:45:42Z","timestamp":1678509942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-009-9320-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,16]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["9320"],"URL":"https:\/\/doi.org\/10.1007\/s10637-009-9320-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,16]]},"assertion":[{"value":"29 July 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}